Neurocrine Biosciences, Inc. NBIX
This picture changes. Follow Neurocrine Biosciences, Inc. free — email when the signal or risk changes + a Sunday weekly brief.
Follow Neurocrine Biosciences, Inc. freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Full analysis: 31 Jul 2026
Latest news check: 7 Jun 2026
General analysis — not personal advice.
BUY
7/10
Confidence
A full position may be justified at current valuation given the commercial momentum.
Strong revenue growth, profitability and successful acquisition support the add signal even though the stock trades near ATH.
Market sentiment
8/10
↑
Trend: Improving
The market reacts positively to the strong commercial performance and successful integration of VYKAT XR.
Price context
The price of 185.5 USD sits near the 52-week high after +44.7 % over twelve months and reflects market confidence in the diversified growth strategy.
Risk assessment
4/10
Dilution:
Low
Strong cash position and positive cash flow
Jurisdiction:
Low
Primary operations in the USA
Execution:
Medium
Proven commercial track record but newer products
About the company
Neurocrine Biosciences develops and commercializes medicines targeting neurological, psychiatric and endocrine disorders. The company has two commercial products INGREZZA and CRENESSITY and recently added VYKAT XR through the Soleno acquisition. Operations are profitable with strong growth and a late-stage pipeline.
Sector:
Biotech focused on neurology, psychiatry and endocrinology
Type:
Biotech
Next report
15 Oct 2026
Q3
Catalysts
Q2 2027
Phase 3 data osavampator
High
Q2 2027
Phase 3 data direclidine
High
Horizon:
Bull case
Strong Q2 report with 39 % revenue growth and raised INGREZZA guidance creates positive momentum.
Bear case
Stock trades near 52-week high with high expectations already priced in and limited news flow during 2026.
Sensitivity analysis
| Factor | If it weakens | If it strengthens |
|---|---|---|
| INGREZZA sales | Lower than expected growth → reduced cash generation and lower profitability. | Higher than expected growth → strengthened cash position and room for further pipeline investment. |
| Phase 3 data for osavampator and direclidine | Failed or delayed readouts → limited pipeline diversification and lower long-term growth. | Positive readouts → new approvals and significant market expansion in psychiatry. |
We monitor these factors. Follow the company to get email when any of them hit.
Signal rationale (informational)
Strong revenue growth, profitability and successful acquisition support the add signal even though the stock trades near ATH.
Recent news
- The Q2 report released 30 July 2026 significantly beat expectations with Non-GAAP EPS of 2.85 USD and revenue of 959 M USD. The company raised full-year INGREZZA guidance and completed the Soleno acquisition.
Key figures
Revenue
Q2 2026
USD 959M
EBITDA
Q3 2025
USD 200M
Net income
Q2 2026
USD 144M
Cash
Q2 2026
USD 491M
Gross margin
Q3 2025
90.0%
Shares outstanding
Q2 2026
101M
EPS
Q2 2026
USD 1.43
Price & valuation
Last close
USD 165
Market Cap
USD 16.6B
1 week
+2.1 %
3 months
+2.2 %
12 months
+28.0 %
From 52w high
-11.1 %
From 52w low
+34.0 %
Exchange
NASDAQ
Type
Biotech
Sector
Biotech focused on neurology, psychiatry and endocrinology
This picture changes. Follow Neurocrine Biosciences, Inc. free — email when the signal or risk changes + a Sunday weekly brief.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.